Elicio Therapeutics Inc. Total Assets
Elicio Therapeutics Inc. total assets. Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) holds total assets worth $31.33 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Elicio Therapeutics Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Elicio Therapeutics Inc. (2012–2025)
Total assets of Elicio Therapeutics Inc. from 2012 to 2025. This chart illustrates how Elicio Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See ELTX stock price and chart for real-time trading data and today's change.
Elicio Therapeutics Inc. - Asset Composition Analysis
Elicio Therapeutics Inc. Total Assets Breakdown (December 2025)
Elicio Therapeutics Inc. total assets breakdown as of December 2025. Elicio Therapeutics Inc.'s total assets of $31.33 Million consist of 74.7% current assets and 25.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Elicio Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Elicio Therapeutics Inc. (ELTX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elicio Therapeutics Inc.'s current assets represent 74.7% of total assets in 2025, an increase from 18.7% in 2012.
- Cash Position: Cash and equivalents constituted 71.8% of total assets in 2025, up from 12.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Elicio Therapeutics Inc. Competitors by Total Assets
Key competitors of Elicio Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
USA | $1.74 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
PYC Therapeutics Ltd
AU:PYC
|
Australia | AU$183.28 Million |
Elicio Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 2.28 | 5.83 |
| Quick Ratio | 2.77 | 2.28 | 5.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.28 Million | $12.68 Million | $99.18 Million |
Elicio Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Elicio Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.75 |
| Latest Market Cap to Assets Ratio | 1.67 |
| Asset Growth Rate (YoY) | -8.2% |
| Total Assets | $25.86 Million |
| Market Capitalization | $43.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values Elicio Therapeutics Inc.'s assets above their book value (1.67x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Elicio Therapeutics Inc.'s assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual total assets of Elicio Therapeutics Inc. from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $25.86 Million | -8.22% |
| 2024-12-31 | $28.18 Million | +3.80% |
| 2023-12-31 | $27.15 Million | +19.78% |
| 2022-12-31 | $22.66 Million | -76.52% |
| 2021-12-31 | $96.51 Million | +103.84% |
| 2020-12-31 | $47.35 Million | +298.34% |
| 2019-12-31 | $11.89 Million | -55.36% |
| 2018-12-31 | $26.63 Million | +140.70% |
| 2013-12-31 | $11.06 Million | +0.30% |
| 2012-12-31 | $11.03 Million | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more